NASDAQ Forest Labs is also working on extending the product's lifecycle and is conducting a phase III study with a fixed dose combination of Bystolic and valsartan (the market leader) for hypertension. A fixed dose combination product would expand the patient ... and more »
Journal of Clinical Endocrinology and Metabolism Address all correspondence and requests for reprints to: G. H. Goossens, PhD, Maastricht University Medical Center, Department of Human Biology (NUTRIM), PO Box 616, 6200 MD Maastricht, The Netherlands. E-mail: G.Goossens{at}maastrichtuniversity.nl.
